FINWIRES · TerminalLIVE
FINWIRES

Rani Therapeutics Reports Positive Initial Phase 1a Data for RT-114 in Obesity

By

Rani Therapeutics (RANI) reported positive initial phase 1a data for RT-114 showing oral bioavailability exceeded that of a matched subcutaneous dose in healthy volunteers, the company said Wednesday.

Oral RT-114 achieved systemic exposure of more than 150% relative to a matched 12-milligram subcutaneous dose of PG-102, Rani Therapeutics said.

No serious adverse events were reported, and treatment-related adverse events were mild and consistent with the known profile of GLP-1/GLP-2 dual agonists, the company said.

Rani Therapeutics also said it has expanded the phase 1a study with an additional cohort to further evaluate the oral-to-subcutaneous pharmacokinetic relationship before starting a planned phase 1b repeat-dose study in patients with obesity later this year.

Data from the phase 1b study are expected in 2027, Rani Therapeutics said.

Shares of the company were 6.5% higher in premarket trading.

Related Articles

Wire

Rio Tinto Group's Q2 Update Shows Production in Line With Consensus, Says Jefferies

Rio Tinto Group (ASX:RIO) reported second quarter production exceeding expectations for Pilbara iron ore production and shipments, while performance across its other major operating assets was also broadly in line with market forecasts, according to a Wednesday Jefferies note.The investment firm added that the company has reduced unit cost guidance in copper to $0.30 to $0.50 per pound from $0.65 to $0.75 per pound due to higher gold prices and operational improvement initiatives."While mostly an uneventful report from Rio, the [quarter-on-quarter] rebound in volumes at certain assets in 2Q is encouraging," the investment firm said.Jefferies kept a hold rating on Rio Tinto with a price target of AU$187.The company's shares rose past 1% in recent Wednesday trade.

ASX:RIO
Wire

Copa Holdings Reports Higher June Passenger Capacity, Traffic

Copa Holdings (CPA) said its preliminary June passenger capacity, measured as available seat miles, increased 16% from a year earlier.Passenger traffic, measured as revenue passenger miles, rose 13%, the company said Tuesday in a statement.Copa shares gained 3.1% in after-hours trading.

$CPA
Wire

Phoenix Education Partners Fiscal Q3 Adjusted Earnings Fall, Revenue Rises; Shares Drop After Hours

Phoenix Education Partners (PXED) reported fiscal Q3 adjusted earnings late Tuesday of $1.43 per diluted share, down from $1.57 a year earlier.Analysts polled by FactSet expected $1.32.Revenue in the three months ended May 31 rose to $271.8 million from $271.7 million a year earlier. Analysts expected $271.2 million.Phoenix expects full-year net revenue of $1.02 billion to $1.025 billion. Analysts expect $1.026 billion.The company's shares fell 11% in after-hours trading.

$PXED